Kira Sheinerman Ph.D.

Kira Sheinerman, PhD, MBA has had extensive work experience in various roles and companies in the field of healthcare investment, molecular diagnostics, and neurodegenerative conditions. Kira served as a Board Member at Boyce Thompson Institute since 2010. In 2009, they founded and worked as the Chief Executive Officer of DiamiR, a molecular diagnostics company focused on developing tests for early detection and monitoring of neurodegenerative and neurological diseases. Kira was also a Managing Director of Investment Banking at H.C. Wainwright & Co., LLC from 2015. Additionally, they served as a Co-Chair of the Alzheimer's Association Business Consortium from 2015 to 2018. Kira held roles in healthcare investment banking at Burrill & Company and Rodman & Renshaw. Kira has also served on the board of Xenomics Inc. and worked as an Associate at Arcus Group.

Kira Sheinerman, PhD, MBA, began their education in 1994 at the Icahn School of Medicine at Mount Sinai, where they pursued a Doctor of Philosophy degree in Biomedical Sciences. Kira completed their PhD program in 2000 after six years of study. In 2001, they enrolled at Baruch College and pursued a Master of Business Administration (MBA) degree, which they completed in 2003. No specific field of study was mentioned for their MBA program.